Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that alopecia areata is significantly associated with thyroid autoimmunity, but not with clinical or subclinical thyroid disease, in the Pakistani population.

This paper discusses tinea capitis in adults, emphasizing that it particularly affects postmenopausal African American or Black women, and notes challenges in treatment due to antifungal resistance.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This article discusses the patterns and variants of alopecia areata, including the rare sisaipho, but reports no new research findings.

In this study, reversible ageusia in a patient was strongly suggested to be caused by losartan, with potential implications for angiotensin receptor involvement in taste disturbance.

This study observed that JAK inhibitors were effective and safe for treating alopecia totalis and universalis, with improved response rates seen most with ritlecitinib and tofacitinib by week 24.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This paper reviews current treatments for alopecia areata and emphasizes the importance of tailoring therapy to each patient's specific condition and needs without reporting new clinical results.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This case report details a 29-year-old male with recurrent alopecia areata who achieved complete hair regrowth after five months of Ayurvedic treatments, including Virechan therapy, Shamana Chikitsa, and Jalaukavacharana, with no adverse effects.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study found that Finnish individuals with alopecia areata, especially those with significant hair loss, reported reduced well-being and significant comorbidities, highlighting unmet needs for treatment and professional support.

This study found that children with alopecia areata had more neglectful family environments and higher levels of anxiety and depression compared to healthy control peers, suggesting a psychosomatic component to the condition.

In this cross-sectional study conducted at Farhat Hached Hospital in Tunisia, more than half of the 60 alopecia areata patients surveyed experienced depression, particularly younger individuals and those with severe or specific forms of the condition, underscoring the need for psychological support.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This study found that mild skin injuries in rats, especially those dosed with dihydrotachysterol, lead to mineral deposits in hair follicle tissue within 6-12 hours, as confirmed by chemical and X-ray diffraction analyses.

This study observed that children with alopecia areata had higher anxiety and depression scores, and their families showed more neglectful parenting styles compared to healthy controls.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

Calcipotriol may effectively treat hair loss in alopecia areata, working better in children than adults.

This study found that etretinate treatment led to an increase in plucked telogen hair counts, suggesting a reduction in the duration of anagen as the primary cause.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.

This article discusses contact dermatitis linked to alopecia and hyperpigmentation, but it reports no new clinical results.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.